Payment overview · 2025
General Payments
$944.96
59 reported records · 12 companies
Healthcare provider profile · identity verified
David Stahl, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MIDDLEPORT, NY · NPI 1255313391
Verified facts
What the public records show
CMS Open Payments records show David Stahl, M.D. received $944.96 in general payments during 2025 across 59 reported records.
Novo Nordisk Inc accounted for 60.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Brilinta by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 381 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 381 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $574.95 | 60.8% | 41 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $104.01 | 11.0% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $65.42 | 6.9% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $46.53 | 4.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.10 | 2.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.84 | 2.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.27 | 2.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.19 | 2.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.77 | 2.0% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $18.48 | 2.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.52 | 1.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.88 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $944.96 | 59 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $429.34 | 34 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $257.83 | 21 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $119.28 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $65.42 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $60.03 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $46.53 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $45.49 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $27.10 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $27.10 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $23.44 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.54 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.19 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $18.77 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.88 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 381 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 150 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 119 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
381 | 67 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
119 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
150 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
381 | 67 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1324 | 255 |
| Metoprolol Succinate | Metoprolol Succinate | 1295 | 233 |
| Amlodipine Besylate | Amlodipine Besylate | 865 | 178 |
| Omeprazole | Omeprazole | 687 | 149 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 648 | 145 |
| Gabapentin | Gabapentin | 643 | 134 |
| Levothyroxine Sodium | Levothyroxine Sodium | 601 | 120 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 582 | 124 |
| Furosemide | Furosemide | 549 | 127 |
| Pantoprazole Sodium | Pantoprazole Sodium | 548 | 103 |
| Lisinopril | Lisinopril | 534 | 126 |
| Metformin Hcl | Metformin Hcl | 483 | 111 |
| Tamsulosin Hcl | Tamsulosin Hcl | 479 | 99 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 413 | 84 |
| Losartan Potassium | Losartan Potassium | 405 | 93 |
| Trazodone Hcl | Trazodone Hcl | 390 | 65 |
| Prednisone | Prednisone | 385 | 118 |
| Eliquis | Apixaban | 381 | 67 |
| Metoprolol Tartrate | Metoprolol Tartrate | 347 | 67 |
| Pregabalin | Pregabalin | 320 | 61 |
| Famotidine | Famotidine | 314 | 58 |
| Finasteride | Finasteride | 267 | 50 |
| Lorazepam | Lorazepam | 225 | 58 |
| Simvastatin | Simvastatin | 223 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 218 | 47 |
| Sertraline Hcl | Sertraline Hcl | 211 | 43 |
| Atenolol | Atenolol | 205 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 203 | 46 |
| Baclofen | Baclofen | 198 | 48 |
| Glimepiride | Glimepiride | 195 | 38 |
| Donepezil Hcl | Donepezil Hcl | 190 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 182 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 179 | 45 |
| Amitriptyline Hcl | Amitriptyline Hcl | 177 | 32 |
| Meloxicam | Meloxicam | 174 | 38 |
| Potassium Chloride | Potassium Chloride | 167 | 34 |
| Xarelto | Rivaroxaban | 166 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 164 | 36 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 162 | 67 |
| Alprazolam | Alprazolam | 161 | 40 |
| Ozempic | Semaglutide | 150 | 26 |
| Celecoxib | Celecoxib | 149 | 32 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 148 | 19 |
| Meclizine Hcl | Meclizine Hcl | 147 | 39 |
| Bumetanide | Bumetanide | 143 | 41 |
| Levofloxacin | Levofloxacin | 142 | 114 |
| Pravastatin Sodium | Pravastatin Sodium | 142 | 33 |
| Clonidine Hcl | Clonidine Hcl | 139 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 134 | 35 |
| Mirtazapine | Mirtazapine | 123 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 120 | 43 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 119 | 22 |
| Tramadol Hcl | Tramadol Hcl | 115 | 34 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 108 | 19 |
| Ibuprofen | Ibuprofen | 105 | 30 |
| Allopurinol | Allopurinol | 101 | 25 |
| Metformin Hcl Er | Metformin Hcl | 98 | 25 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 96 | 22 |
| Carvedilol | Carvedilol | 90 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 87 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 87 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 86 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 86 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 85 | 17 |
| Nifedipine Er | Nifedipine | 85 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 77 | 58 |
| Tresiba Flextouch U-200 | Insulin Degludec | 75 | 23 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 72 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 72 | 12 |
| Clonazepam | Clonazepam | 68 | 15 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 68 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | 11 |
| Nystatin | Nystatin | 65 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 63 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 62 | 18 |
| Levetiracetam | Levetiracetam | 62 | 11 |
| Methotrexate | Methotrexate Sodium | 62 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | 14 |
| Warfarin Sodium | Warfarin Sodium | 56 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 55 | 42 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 54 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | suppressed |
| Azithromycin | Azithromycin | 51 | 41 |
| Verapamil Er | Verapamil Hcl | 51 | suppressed |
| Metolazone | Metolazone | 50 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 35 |
| Sumatriptan Succinate | Sumatriptan Succinate | 48 | 11 |
| Glipizide Er | Glipizide | 47 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 22 |
| Ulticare Pen Needle | Pen Needle, Diabetic | 45 | 15 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 44 | 21 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 43 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 42 | suppressed |
| Irbesartan | Irbesartan | 42 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 41 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 38 | suppressed |
| Diazepam | Diazepam | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 37 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 37 | 13 |
| Glipizide | Glipizide | 37 | suppressed |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Synthroid | Levothyroxine Sodium | 37 | suppressed |
| Testosterone | Testosterone | 36 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 35 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 34 | suppressed |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Gemfibrozil | Gemfibrozil | 32 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Spironolactone | Spironolactone | 32 | 13 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 32 | suppressed |
| Digoxin | Digoxin | 30 | suppressed |
| Fentanyl | Fentanyl | 30 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Scopolamine | Scopolamine | 30 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Brilinta | Ticagrelor | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 28 | suppressed |
| Oxycontin | Oxycodone Hcl | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 23 |
| Jardiance | Empagliflozin | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 13 |
| Lovastatin | Lovastatin | 24 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 23 | 14 |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 15 |
| Folic Acid | Folic Acid | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Buprenorphine | Buprenorphine | 16 | suppressed |
| Cefdinir | Cefdinir | 16 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Cartia Xt | Diltiazem Hcl | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 13 |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | 12 |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Cimetidine | Cimetidine | 11 | suppressed |
| Clarithromycin | Clarithromycin | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Nexletol | Bempedoic Acid | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Protonix | Pantoprazole Sodium | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Zafirlukast | Zafirlukast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $944.96 · 59 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, Fluad, Flucelvax, Kerendia, MOUNJARO, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, VYNDAMAX, VYNDAQEL, Wegovy, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error